Skip to main content


URMC / Virtual Drug Discovery / Investigators


The following list of investigators have active research in some aspect of drug discovery.

Investigator Research Focus Department
Rashid Deane, Ph.D. Small molecule therapeutics for neurodegenerative diseases, including Alzheimer's disease Neurosurgery
Paul Dunman, Ph. D. High throughput screening for novel anti bacterial agents Microbiology & Immunology
Rudi Fasan, Ph. D. Chemo-enzymatic synthesis of natural product derivatives with anticancer and antimalarial activity Chemistry
Jonathan Friedberg, M.D. Kinase inhibitors for treatment of Iymphoma Medicine
Harris Gelbard, M. D. Development of drugs for age-related and inflammatory diseases that target ancient caloric restriction pathways Neurology
David Goldfarb, Ph.D. High throughput identification and development of novel lifespan extending compounds Biology
Craig Jordan, Ph.D. Novel small molecules to selectively target leukemia cells Medicine
Karl Kieburtz, M.D. Human clinical studies of novel therapeutics for various diseases Neurology
Damian Krysan, Ph.D. Antifungal drug discovery Pediatrics
Hartmut Land, Ph.D. Gene interactions in oncogenesis Biomedical Genetics
Joe Miano, Ph.D. Small molecule inhibitors of genes that regulate pathologic blood vessel contraction Medicine
Ben Miller, Ph.D. Chemical synthesis of small molecule ligands; novel RNA-directed therapies for HIV/AIDS Dermatology
Alan Smrcka, Ph.D. High throughput identification of novel inhibitors of G beta gamma signaling Pharmacology & Physiology
Harold Smith, Ph.D. Small molecule drugs targeting HIV-1 Vif and APOBEC3G Biochemistry & Biophysics
Harry Stern, Ph.D. Small molecule docking and affinity calculations Chemistry
Charles Thornton, M.D. Novel therapeutics targeting triplet repeat transcripts for treatment of myotonic muscular dystrophy Neurology
Joseph Wedekind, Ph.D. Structural analysis of HIV-1 Vif and APOBEC3G Biochemistry & Biophysics